(Q37927089)

25 August 2017

1 reference

title

The clinical development of FLT3 inhibitors in acute myeloid leukemia (English)

1 reference

25 August 2017

1 reference

Steven Knapper

1

1 reference

25 August 2017

language of work or name

English

0 references

publication date

6 September 2011

1 reference

Expert Opinion on Investigational Drugs

25 August 2017

published in

1 reference

25 August 2017

volume

20

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1377-1395

1 reference

The role of FLT3 in haematopoietic malignancies

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Flt3 mutations and leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3 inhibition in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Novel FLT3 tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3 as a therapeutic target in AML: still challenging after all these years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The structural basis for autoinhibition of FLT3 by the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3: ITDoes matter in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Clinical implications of FLT3 mutations in pediatric AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Rational design of inhibitors that bind to inactive kinase conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

IMC-EB10, an anti-FLT3 monoclonal antibody, prolongs survival and reduces nonobese diabetic/severe combined immunodeficient engraftment of some acute lymphoblastic leukemia cell lines and primary leukemic samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Internal tandem duplications of the FLT3 gene are present in leukemia stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Heterogeneous patterns of FLT3 Asp(835) mutations in relapsed de novo acute myeloid leukemia: a comparative analysis of 120 paired diagnostic and relapse bone marrow samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.611802

10.1517/13543784.2011.611802

21 January 2018

Identifiers

DOI

1 reference

release_5vmendykurgoznej4ru7s7wjwq

25 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5vmendykurgoznej4ru7s7wjwq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference